Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy.

TitlePretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy.
Publication TypeJournal Article
Year of Publication2007
AuthorsBosch RJ, Bennett K, Collier AC, Zackin R, Benson CA
JournalJ Acquir Immune Defic Syndr
Volume44
Issue3
Pagination268-77
Date Published2007 Mar 1
ISSN1525-4135
KeywordsAdult, Age Factors, Anti-HIV Agents, CD4 Lymphocyte Count, Drug Therapy, Combination, Ethnic Groups, Female, HIV Infections, Humans, Male, Middle Aged, Regression Analysis, RNA, Viral, Sex Factors, Statistics as Topic, Treatment Outcome
Abstract

OBJECTIVE: To examine pretreatment factors associated with longer term (144 weeks) responses to antiretroviral therapy (ART).

METHODS: Of 1498 ART-naive subjects randomized to ART regimens, including > or =3 agents, 1083 patients who had plasma HIV RNA (vRNA) levels and CD4 cell counts at baseline and week 144 were analyzed. Primary baseline factors evaluated were CD4 cell count, vRNA level, gender, race, and age, using multivariable Cox, log-binomial, and linear regression models.

RESULTS: Shorter time to achieving a vRNA level <50 copies/mL was associated with lower baseline vRNA level (P < 0.001), older age (P = 0.007), and lower baseline CD4 cell count (P = 0.055). After adjusting for race, gender, and baseline CD4 cell count, older age was associated with a vRNA level <50 copies/mL at week 144 (P = 0.018). Greater CD4 count increases from baseline to week 144 (mean = 284 cells/microL) were seen in younger men, blacks, and subjects with higher pretreatment vRNA levels; the effect of pretreatment vRNA level was most apparent in women.

CONCLUSIONS: Older age was the most important baseline predictor of a vRNA level <50 copies/mL at week 144; lower pretreatment vRNA level and older age were the most important predictors of time to a vRNA level <50 copies/mL. The influence of pretreatment factors on increases in CD4 cell counts differed between men and women.

DOI10.1097/QAI.0b013e31802c7e20
Alternate JournalJ. Acquir. Immune Defic. Syndr.
PubMed ID17146370
Grant ListAI 27660 / AI / NIAID NIH HHS / United States
AI 25859 / AI / NIAID NIH HHS / United States
AI 25868 / AI / NIAID NIH HHS / United States
AI 25879 / AI / NIAID NIH HHS / United States
AI 25897 / AI / NIAID NIH HHS / United States
AI 25903 / AI / NIAID NIH HHS / United States
AI 25915 / AI / NIAID NIH HHS / United States
AI 25924 / AI / NIAID NIH HHS / United States
AI 27658 / AI / NIAID NIH HHS / United States
AI 27659 / AI / NIAID NIH HHS / United States
AI 27661 / AI / NIAID NIH HHS / United States
AI 27664 / AI / NIAID NIH HHS / United States
AI 27665 / AI / NIAID NIH HHS / United States
AI 27668 / AI / NIAID NIH HHS / United States
AI 27670 / AI / NIAID NIH HHS / United States
AI 27673 / AI / NIAID NIH HHS / United States
AI 27675 / AI / NIAID NIH HHS / United States
AI 32770 / AI / NIAID NIH HHS / United States
AI 32775 / AI / NIAID NIH HHS / United States
AI 32782 / AI / NIAID NIH HHS / United States
AI 34832 / AI / NIAID NIH HHS / United States
AI 34853 / AI / NIAID NIH HHS / United States
AI 38855 / AI / NIAID NIH HHS / United States
AI 38858 / AI / NIAID NIH HHS / United States
AI 39156 / AI / NIAID NIH HHS / United States
AI 46339 / AI / NIAID NIH HHS / United States
AI 46370 / AI / NIAID NIH HHS / United States
AI 46376 / AI / NIAID NIH HHS / United States
AI 46381 / AI / NIAID NIH HHS / United States
AI 46383 / AI / NIAID NIH HHS / United States
AI 46386 / AI / NIAID NIH HHS / United States
AI 50410 / AI / NIAID NIH HHS / United States
RR 00046 / RR / NCRR NIH HHS / United States
RR 00047 / RR / NCRR NIH HHS / United States
RR 00051-2 / RR / NCRR NIH HHS / United States
RR 00096 / RR / NCRR NIH HHS / United States